Fig. 1: ctDNA analysis in high-risk early-stage breast cancer receiving neoadjuvant therapy (NAT).
From: Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors
A Blood samples for ctDNA analysis were collected at pretreatment (T0), 3 weeks after initiation of paclitaxel treatment with or without an investigational drug (T1), at 12 weeks post-paclitaxel treatment before the anthracycline (AC) regimen (T2), and post-NAT before surgery (T3). The survival endpoint was distant recurrence-free survival (DRFS), and the response endpoints were RCB score and RCB class. B Inclusion or exclusion of patients and samples from the analyses based on evaluability and quality control metrics. C Analytic pipeline for clinical and correlative studies.
